Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sang-Qi Granula for vascular endothelial dysfunction in primary hypertension
ChiCTR1800016427Phase 3Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Jan 2018
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Sang-Qi Granula and losartan in essential hypertension (3 arms), sponsored by China-Japan Friendship Hospital. Primary endpoints: Blood pressure, Vascular endothelial function and 1 more. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
Sang-Qi Granulalosartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR1800016427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016427.